Filing Flows › Regenerative Medical Technology Group (RMTG) › Q4 2025
Regenerative Medical Technology Group (RMTG) Q4 2025 earnings results (fourth quarter 2025)
10-K filed May 14, 2026
Regenerative Medical Technology Group (RMTG) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), +4% from a year earlier and +33% from the quarter before. Operating margin was -19.5%, net loss $1.4M (88.6% of revenue).
Regenerative Medical Technology Group, Q4 2025: revenue $1.6M (+4% year over year), operating margin -19.5%, net loss $1.4M, operating cash flow $38K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | +33% | +4% |
| Operating profit | −$306K | — | -180% |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | $38K | — | -90% |
What changed
Revenue was $1.6M in Q4 2025, up 4% year over year and up 33% from the previous quarter. Product Supplies was the largest line at 41% of revenue.
Gross margin was 49.6%, down 15.3 points from Q4 2024. Operating costs exceeded revenue by $306K, an operating margin of -19.5%. Operating expenses grew 81% against revenue growth of 4%. The fastest-growing cost line was General & admin (+244%). The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $4.4M loss. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was $38K (down 90% year over year). Non-cash charges added back $98K of depreciation and amortization. Working capital and other items added $1.3M. Capital expenditures of $267K exceeded it, leaving free cash flow of −$229K.
Questions
What was Regenerative Medical Technology Group's revenue in the fourth quarter 2025?
Regenerative Medical Technology Group (RMTG) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), +4% from a year earlier and +33% from the quarter before.
Was Regenerative Medical Technology Group profitable in the fourth quarter 2025?
Operating loss was $306K (-19.5% of revenue) and net loss $1.4M.
Source: Regenerative Medical Technology Group 10-K on SEC EDGAR.